These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 1787609)
1. Neoadjuvant chemotherapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 69 cases of locally advanced (stage IIIb) breast cancer. Gupta P; Bijlani L; Rath GK; Misra A; Mishra MC; Shukla NK; Kriplani A; Kapur BM Jpn J Surg; 1991 Nov; 21(6):637-42. PubMed ID: 1787609 [TBL] [Abstract][Full Text] [Related]
2. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG). Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086 [TBL] [Abstract][Full Text] [Related]
3. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer. Erol K; Baltali E; Altundag K; Guler N; Ozisik Y; Onat DA; Sayek I; Cengiz M; Atahan L; Tekuzman G Onkologie; 2005 Feb; 28(2):81-5. PubMed ID: 15662111 [TBL] [Abstract][Full Text] [Related]
5. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Kimmick GG; Cirrincione C; Duggan DB; Bhalla K; Robert N; Berry D; Norton L; Lemke S; Henderson IC; Hudis C; Winer E; Breast Cancer Res Treat; 2009 Feb; 113(3):479-90. PubMed ID: 18306034 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211 [TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results. Colozza M; Gori S; Mosconi AM; Anastasi P; de Angelis V; Giansanti M; Mercati U; Aristei C; Latini P; Tonato M Am J Clin Oncol; 1996 Feb; 19(1):10-7. PubMed ID: 8554028 [TBL] [Abstract][Full Text] [Related]
9. Surgical adjuvant chemotherapy for breast cancer: a comparison of CMF and CAF regimens. Babar AM J Pak Med Assoc; 1991 Dec; 41(12):293-6. PubMed ID: 1824559 [TBL] [Abstract][Full Text] [Related]
10. Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience. Leone JP; Leone J; Vallejo CT; Pérez JE; Romero AO; Machiavelli MR; Romero Acuña L; Domínguez ME; Langui M; Fasce HM; Leone BA; Ortiz E; Iturbe J; Zwenger AO Breast Cancer Res Treat; 2014 Jan; 143(2):313-23. PubMed ID: 24327333 [TBL] [Abstract][Full Text] [Related]
11. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862 [TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452 [TBL] [Abstract][Full Text] [Related]
13. Multimodality treatment of noninflammatory stage IIIb breast cancer. Gliński B; Pawlicki M; Reinfuss M; Skołyszewski J; Brandys A; Krzemieniecki K; Zuchowska B; Mitus J; Stelmach A; Walasek T J Surg Oncol; 1997 Nov; 66(3):179-85. PubMed ID: 9369963 [TBL] [Abstract][Full Text] [Related]
14. Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer. Livi L; Saieva C; Borghesi S; De Luca Cardillo C; Scotti V; Mangoni M; Greto D; Cataliotti L; Paiar F; Bianchi S; Biti GP J Chemother; 2009 Nov; 21(5):558-65. PubMed ID: 19933048 [TBL] [Abstract][Full Text] [Related]
15. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. Brito RA; Valero V; Buzdar AU; Booser DJ; Ames F; Strom E; Ross M; Theriault RL; Frye D; Kau SW; Asmar L; McNeese M; Singletary SE; Hortobagyi GN J Clin Oncol; 2001 Feb; 19(3):628-33. PubMed ID: 11157012 [TBL] [Abstract][Full Text] [Related]
16. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326 [TBL] [Abstract][Full Text] [Related]
17. Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer. Falkson G; Tormey DC; Carey P; Witte R; Falkson HC Eur J Cancer; 1991; 27(8):973-7. PubMed ID: 1832906 [TBL] [Abstract][Full Text] [Related]
18. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228 [TBL] [Abstract][Full Text] [Related]
19. The use of neoadjuvant CMF to avoid mastectomy. George ML; Hale PC; Gumpert JR; Hogbin BM; Deutsch GP; Yelland A Eur J Surg Oncol; 1999 Feb; 25(1):50-3. PubMed ID: 10188855 [TBL] [Abstract][Full Text] [Related]
20. The role of surgery in the combined treatment of locally advanced breast cancer. Canavese G; Catturich A; Battistini G; Caroti C; Pronzato P; Gardin G; Amoroso D; Bertelli G; Conte PF; Tomao S Oncology; 1989; 46(6):353-6. PubMed ID: 2587002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]